Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Cell Transplant 29:963689720927392 Peters CT, Choi YH, Brubaker PL, Anderson GH (2001) A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats
F.FleurS
L-Carnitine Magnesium - Aspartate - Hydrocholoride (MAH) Water Potassium Sorbate (preservative)
Each pathway contributes a separate pharmacological signal: GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market How retatrutide compares to dual agonists Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023
Both work similarly but may have slightly different dosing protocols
Retatrutide is a next-generation peptide that simultaneously activates multiple metabolic signaling pathways, including glucagon-like peptide receptors involved in appetite and glucose regulation
US$ 26.48
US$ 24.94
US$ 27.21
